CO2022015737A2 - Anticuerpos anti-phf-tau y usos de los mismos - Google Patents

Anticuerpos anti-phf-tau y usos de los mismos

Info

Publication number
CO2022015737A2
CO2022015737A2 CONC2022/0015737A CO2022015737A CO2022015737A2 CO 2022015737 A2 CO2022015737 A2 CO 2022015737A2 CO 2022015737 A CO2022015737 A CO 2022015737A CO 2022015737 A2 CO2022015737 A2 CO 2022015737A2
Authority
CO
Colombia
Prior art keywords
container
pull tab
phf
package
tau antibodies
Prior art date
Application number
CONC2022/0015737A
Other languages
English (en)
Spanish (es)
Inventor
Jinquan Luo
Marc Mercken
Sanjaya Singh
Porte Sherry La
Sathyadevi Venkataramani
Kolen Kristof Van
Rupesh Nanjunda
Pharavee Jaiprasart
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CO2022015737A2 publication Critical patent/CO2022015737A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CONC2022/0015737A 2020-04-08 2022-10-31 Anticuerpos anti-phf-tau y usos de los mismos CO2022015737A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2022015737A2 true CO2022015737A2 (es) 2023-02-27

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015737A CO2022015737A2 (es) 2020-04-08 2022-10-31 Anticuerpos anti-phf-tau y usos de los mismos

Country Status (20)

Country Link
US (1) US20230151083A1 (https=)
EP (1) EP4132569A4 (https=)
JP (1) JP2023521763A (https=)
KR (1) KR20220166308A (https=)
CN (1) CN115697393A (https=)
AU (1) AU2021251486A1 (https=)
BR (1) BR112022020410A2 (https=)
CA (1) CA3179914A1 (https=)
CL (1) CL2022002766A1 (https=)
CO (1) CO2022015737A2 (https=)
CR (1) CR20220505A (https=)
DO (1) DOP2022000218A (https=)
EC (1) ECSP22078815A (https=)
IL (1) IL297231A (https=)
JO (1) JOP20220255A1 (https=)
MX (1) MX2022012628A (https=)
PE (1) PE20230385A1 (https=)
PH (1) PH12022553035A1 (https=)
TW (1) TW202204402A (https=)
WO (1) WO2021205359A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
CA3254442A1 (en) * 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv MULTISPECIFIC ANTIBODIES AND THEIR USES
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350311B (es) * 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US10344081B2 (en) * 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
US10591492B2 (en) * 2018-03-05 2020-03-17 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
CA3179922A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Anti-cd98 antibodies and uses thereof
CN121754667A (zh) * 2020-04-08 2026-03-31 阿里亚达治疗公司 用于血脑屏障递送的组合物和方法

Also Published As

Publication number Publication date
CL2022002766A1 (es) 2023-04-21
CA3179914A1 (en) 2021-10-14
WO2021205359A1 (en) 2021-10-14
AU2021251486A1 (en) 2022-12-08
CN115697393A (zh) 2023-02-03
BR112022020410A2 (pt) 2023-01-03
EP4132569A1 (en) 2023-02-15
PE20230385A1 (es) 2023-03-06
IL297231A (en) 2022-12-01
EP4132569A4 (en) 2024-07-31
US20230151083A1 (en) 2023-05-18
MX2022012628A (es) 2023-01-11
ECSP22078815A (es) 2022-11-30
PH12022553035A1 (en) 2024-05-13
JOP20220255A1 (ar) 2022-10-06
KR20220166308A (ko) 2022-12-16
DOP2022000218A (es) 2023-04-30
JP2023521763A (ja) 2023-05-25
TW202204402A (zh) 2022-02-01
CR20220505A (es) 2023-05-31

Similar Documents

Publication Publication Date Title
CO2022015737A2 (es) Anticuerpos anti-phf-tau y usos de los mismos
AR046175A1 (es) Una valvula unidireccional liberadora de presion aplicable a un envase que contiene un producto que emite gases, en la que coexisten un medio fluido y una burbuja de aire, y un envase que incluye a dicha valvula
RU2010140905A (ru) Обратный клапан
CO2017001972A2 (es) Espita dispensadora de líquido, en especial para dispensar líquidos con densidades más altas desde recipientes rígidos
MX2009005374A (es) Dispositivo para suministrar, por medio de una bomba, sustancias fluidas contenidas bajo condiciones hermeticas al aire en una bolsa deformable alojada en un recipiente rigido.
AR043240A1 (es) Envoltura termo-contraible
BR112012027166A2 (pt) cápsula de liberação por fixação a uma boca de um recipiente receptor.
NO118830B (https=)
ES2014547A6 (es) Procedimiento y dispositivo para llenar asepticamente con un fluido un envase.
AR089664A1 (es) Cierre de recipiente para vertido con venteo a traves de una abertura curva
CO2022010531A2 (es) Dispensador para verter un fluido
CO2020008831A2 (es) Cierre de contenedor con pestaña para jalar indicando vacío
MX2022004583A (es) Tapa para un contenedor.
MX2014004371A (es) Ensamble recolector de sangre.
MX2017009984A (es) Tapadera dispensadora con valvula de cierre automatico.
JP6143769B2 (ja) 中空で取外し可能な蓋を含む容器
MX2021008846A (es) Difusor para recipiente a presion.
AR119458A1 (es) Copela de válvula para recipiente a presión
US996330A (en) Liquid-dropper.
MX2017011097A (es) Revestimientos de lamina de sellado para recipientes.
JP2019107435A (ja) 化粧液保管用アンプル
US1716802A (en) Closure for collapsible tubes
CN203096144U (zh) 水银回吸器
HRPK20100424B3 (hr) Äśep s boäśnim otvorom
MX2022007811A (es) Grifo dispensador de fluido a partir de contenedores rígidos y flexibles, preferentemente del tipo bolsa en caja.